Mammoth Biosciences
Mammoth Biosciences raises $195M Series D at $1B valuation
Quick Facts
Mammoth Biosciences: Series D Funding Round
Mammoth Biosciences has successfully raised $195M in Series D funding, reaching a valuation of $1B.
Company Overview
CRISPR-based diagnostics and therapeutics
Funding Details
The Series D round was led by Decheng Capital, with participation from Greenoaks Capital, Mayfield, NFX, 8VC, Plum Alley Ventures.
Company Information
- Headquarters: 3478 Buskirk Avenue, Pleasant Hill, CA 94523
- Founded: 2017
- Employees: 150+
- Category: Biotech
Investment
Mammoth Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Decheng Capital: Verified investor in Series D
- Greenoaks Capital: Verified investor in Series D
- Mayfield: Verified investor in Series D
- NFX: Verified investor in Series D
- 8VC: Verified investor in Series D
- Plum Alley Ventures: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...